指南与共识流行病学与生物统计临床试验与 GCP

妊娠期糖尿病筛查:美国预防服务工作组推荐声明

Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement.
指南 / 共识 · JAMA · 2021-01-01

USPSTF基于系统综述评估妊娠期糖尿病筛查与治疗的准确性和利弊,结论为对无症状孕妇在24周及以后筛查有中等净获益(B推荐),而24周前筛查证据不足(I声明)。

要点

  • 推荐对无症状孕妇在妊娠24周及以后筛查妊娠期糖尿病(B推荐)。
  • 24周前筛查妊娠期糖尿病的证据不足,无法确定利弊平衡(I声明)。
  • 筛查目标人群为既往未诊断1型或2型糖尿病的孕妇。

核心结论

  • USPSTF以中等确定性认为,在妊娠24周及以后筛查妊娠期糖尿病有中等净获益,可改善母婴结局。
  • USPSTF认为妊娠24周前筛查妊娠期糖尿病的证据不足,无法确定利弊平衡。

研究设计与样本

  • USPSTF委托开展系统综述,评估妊娠期糖尿病筛查的准确性、利弊及治疗对孕妇和婴儿的利弊。
  • 目标人群为既往未诊断1型或2型糖尿病的孕妇。

主要发现

  • 美国妊娠期糖尿病患病率按传统诊断标准估计为5.8%至9.2%,若采用更宽泛标准可能更高。
  • 妊娠期糖尿病孕妇及其胎儿并发症风险增加,包括子痫前期、胎儿巨大儿(可致肩难产和产伤)及新生儿低血糖。
  • 妊娠期糖尿病还与孕妇多种长期健康结局及子代中间结局风险增加相关。

关键数值与推荐

  • 推荐对无症状孕妇在妊娠24周及以后筛查妊娠期糖尿病(B推荐)。
  • 对无症状孕妇在妊娠24周前筛查妊娠期糖尿病的证据不足(I声明)。

临床怎么用

  • 临床应对所有无症状孕妇在妊娠24周及以后安排妊娠期糖尿病筛查。
  • 不常规推荐在妊娠24周前筛查妊娠期糖尿病,除非有额外临床指征。

局限性

  • 24周前筛查妊娠期糖尿病的证据不足,无法评估利弊平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gestational diabetes is diabetes that develops during pregnancy. Prevalence of gestational diabetes in the US has been estimated at 5.8% to 9.2%, based on traditional diagnostic criteria, although it may be higher if more inclusive criteria are used. Pregnant persons with gestational diabetes are at increased risk for maternal and fetal complications, including preeclampsia, fetal macrosomia (which can cause shoulder dystocia and birth injury), and neonatal hypoglycemia. Gestational diabetes has also been associated with an increased risk of several long-term health outcomes in pregnant persons and intermediate outcomes in their offspring. OBJECTIVE: The USPSTF commissioned a systematic review to evaluate the accuracy, benefits, and harms of screening for gestational diabetes and the benefits and harms of treatment for the pregnant person and infant. POPULATION: Pregnant persons who have not been previously diagnosed with type 1 or type 2 diabetes. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for gestational diabetes at 24 weeks of gestation or after to improve maternal and fetal outcomes. The USPSTF concludes that the evidence on screening for gestational diabetes before 24 weeks of gestation is insufficient, and the balance of benefits and harms of screening cannot be determined. RECOMMENDATION: The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for gestational diabetes in asymptomatic pregnant persons before 24 weeks of gestation. (I statement).

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021. PMID: 34374716. doi:10.1001/jama.2021.11922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。